Challenges in understanding Sjögren's syndrome - improved insights into the pathogenesis generate hope for innovative therapies?
CC12, Charite Universitätsmedizin Berlin, Chariteplatz 01, 10098 Berlin, Germany
Arthritis Research & Therapy 2011, 13:123 doi:10.1186/ar3425
See related reviews by Jacob and Stohl, http://arthritis-research.com/content/13/4/228; Shao and Cohen, http://arthritis-research.com/content/13/1/202; Holle et al., http://arthritis-research.com/content/13/3/224; Sipsas et al., http://arthritis-research.com/content/13/2/212; Vitali, http://arthritis-research.com/content/13/4/233; Low and Witte, http://arthritis-research.com/content/13/3/218; Youinou and Pers, http://arthritis-research.com/content/13/4/227; Delaleu et al., http://arthritis-research.com/content/13/3/217; and Kallenberg et al., http://arthritis-research.com/content/13/1/205Published: 19 August 2011
The reviews in this series on Sjögren syndrome provide an up-to-date summary and perspectives on the pathogenesis of this interesting entity with glandular and frequently systemic manifestations, the value of preclinical models, and our current understanding of therapeutic approaches. The last of these includes what has been learned from trials blocking tumor necrosis factor and, more recently, anti-CD20 therapy. Potential therapeutic targets, such as blockade of the B cell-activating factor, the role of interferon-alpha, and targeting CD22, are discussed.